beta
Trial Radar AI
Clinical Trial NCT06718634 for Relapsed or Refractory Lymphoid Malignancies is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1 22 Randomized Open-Label

Recruiting
Clinical Trial NCT06718634 is designed to study Treatment for Relapsed or Refractory Lymphoid Malignancies. It is a Phase 1 interventional study that is recruiting, having started on January 2, 2025, with plans to enroll 22 participants. Led by Sichuan Baili Pharmaceutical Co., Ltd., it is expected to complete by December 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 21, 2026.
Brief Summary
This study is an open-label, multicenter, dose-escalation and extended-enrollment, nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in relapsed or refractory lymphoid malignancies.
Official Title

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Relapsed or Refractory Lymphoid Malignancies

Conditions
Relapsed or Refractory Lymphoid Malignancies
Other Study IDs
  • BL-M08D1-102
NCT ID Number
NCT06718634
Start Date (Actual)
2025-01-02
Last Update Posted
2026-01-21
Completion Date (Estimated)
2027-12
Enrollment (Estimated)
22
Study Type
Interventional
PHASE
Phase 1
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalBL-M08D1
Participants receive BL-M08D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
BL-M08D1
Administration by intravenous infusion for a cycle of 3 weeks.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Phase Ia: Dose limiting toxicity (DLT)
DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.
Up to 21 days after the first dose
Phase Ia: Maximum tolerated dose (MTD)
MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.
Up to 21 days after the first dose
Phase Ib: Recommended Phase II Dose (RP2D)
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M08D1.
Up to approximately 24 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Treatment-Emergent Adverse Event (TEAE)
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M08D1 . The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M08D1.
Up to approximately 24 months
Cmax
Maximum serum concentration (Cmax) of BL-M08D1 will be investigated.
Up to approximately 24 months
Tmax
Time to maximum serum concentration (Tmax) of BL-M08D1 will be investigated.
Up to approximately 24 months
T1/2
Half-life (T1/2) of BL-M08D1 will be investigated.
Up to approximately 24 months
AUC0-t
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.
Up to approximately 24 months
CL (Clearance)
CL in the serum of BL-M08D1 per unit of time will be investigated.
Up to approximately 24 months
Ctrough
Ctrough is defined as the lowest serum concentration of BL-M08D1 prior to the next dose will be administered.
Up to approximately 24 months
ADA (anti-drug antibody)
Frequency of anti-BL-M08D1 antibody (ADA) will be investigated.
Up to approximately 24 months
Phase Ib: Objective Response Rate (ORR)
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
Up to approximately 24 months
Phase Ib: Disease Control Rate (DCR)
The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]).
Up to approximately 24 months
Phase Ib: Duration of Response (DOR)
The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.
Up to approximately 24 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Gender is not limited;
  3. Age: ≥18 years old and ≤75 years old;
  4. Expected survival time ≥3 months;
  5. Recurrent or refractory lymphoid malignancies confirmed by histopathology and/or cytology that are incurable or for which no standard treatment is currently available;
  6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
  7. ECOG≤2;
  8. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  10. Organ function level must meet the requirements;
  11. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;
  12. Urinary protein ≤2+ or ≤1000mg/24h;
  13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (regardless of male or female) should use adequate barrier contraception during the whole treatment cycle and for 6 months after the end of treatment;
  14. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

  1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Palliative radiotherapy or traditional Chinese medicine with anti-tumor indications within 2 weeks before the first dose;
  2. History of severe heart disease;
  3. QT prolongation, complete left bundle branch block, III degree atrioventricular block;
  4. Active autoimmune and inflammatory diseases;
  5. Other malignant tumors diagnosed within 5 years before the first dose;
  6. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
  7. Patients with poor glycemic control or with diabetic gangrene;
  8. A history of ILD requiring steroid therapy or current ILD or grade ≥2 radiation pneumonitis;
  9. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
  10. Patients with central nervous system involvement;
  11. Had a history of or central nervous system disease;
  12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any component of BL-M08D1 excipients;
  13. Received previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  14. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;
  15. Active infection requiring systemic therapy within 4 weeks before the first dose of study drug;
  16. Pleural, abdominal, pelvic or pericardial effusion requiring drainage and/or with symptoms within 4 weeks before the first dose of study drug;
  17. Received another trial drug 4 weeks or 5 half-lives before the first dose;
  18. Pregnant or lactating women;
  19. Other conditions for participation in the trial were not considered appropriate by the investigator.
Sichuan Baili Pharmaceutical Co., Ltd. logoSichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. logoBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study Central Contact
Contact: Sa Xiao, PHD, 15013238943, [email protected]
1 Study Locations in 1 Countries

Heilongjiang

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Qingyuan Zhang, Contact
Recruiting